Nyxoah SA

Nyxoah is a medical technology company specializing in the development and commercialization of innovative solutions for obstructive sleep apnea (OSA) treatment. The company's flagship product is the Genio® system, a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to treat OSA, the world's most common sleep-disordered breathing condition. OSA affects approximately 936 million people globally between ages 30–69, with 425 million suffering from moderate to severe cases requiring treatment. Left untreated, OSA is associated with significant morbidity and mortality, including doubled stroke risk, five-fold increased cardiovascular mortality, and a 140% increased risk of heart failure. The Genio® system offers an alternative to traditional continuous positive airway pressure (CPAP) therapy, addressing the substantial unmet clinical need in sleep medicine. Nyxoah is actively expanding operations and commercializing its lead solution across multiple markets. The company maintains a focus on clinical evidence and patient outcomes in treating this major sleep-disordered breathing condition with significant cardiovascular and systemic implications.